Eli Lilly has strengthened its commitment to artificial intelligence in drug discovery through an expanded partnership with Insilico Medicine, in a deal that could reach up to 2.75 billion dollars.

The agreement grants Lilly exclusive global rights to develop and commercialise selected oral drug candidates generated using Insilico’s AI driven platform. Insilico will receive an upfront payment of 115 million dollars, alongside potential milestone payments and future royalties tied to successful development and market performance.

The collaboration builds on an existing relationship between the companies and reflects a broader industry shift toward AI enabled research. By combining Insilico’s generative AI capabilities with Lilly’s clinical and commercial expertise, the partnership aims to accelerate the identification and development of new therapies across multiple disease areas.

Insilico has already advanced a growing pipeline of AI designed drug candidates, with several progressing into clinical trials. The expanded deal signals increasing confidence in AI as a tool to reduce development timelines and improve R&D efficiency.

For Lilly, the move reinforces its strategy to integrate advanced technologies into its pipeline, positioning the company at the forefront of next generation drug discovery.